Loss of melusin is a novel, neuronal NO synthase/FoxO3-independent master switch of unloading-induced muscle atrophy.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
06 2020
Historique:
received: 04 06 2019
revised: 04 12 2019
accepted: 19 12 2019
pubmed: 11 3 2020
medline: 3 8 2021
entrez: 11 3 2020
Statut: ppublish

Résumé

Unloading/disuse induces skeletal muscle atrophy in bedridden patients and aged people, who cannot prevent it by means of exercise. Because interventions against known atrophy initiators, such as oxidative stress and neuronal NO synthase (nNOS) redistribution, are only partially effective, we investigated the involvement of melusin, a muscle-specific integrin-associated protein and a recognized regulator of protein kinases and mechanotransduction in cardiomyocytes. Muscle atrophy was induced in the rat soleus by tail suspension and in the human vastus lateralis by bed rest. Melusin expression was investigated at the protein and transcript level and after treatment of tail-suspended rats with atrophy initiator inhibitors. Myofiber size, sarcolemmal nNOS activity, FoxO3 myonuclear localization, and myofiber carbonylation of the unloaded rat soleus were studied after in vivo melusin replacement by cDNA electroporation, and muscle force, myofiber size, and atrogene expression after adeno-associated virus infection. In vivo interference of exogenous melusin with dominant-negative kinases and other atrophy attenuators (Grp94 cDNA; 7-nitroindazole) on size of unloaded rat myofibers was also explored. Unloading/disuse reduced muscle melusin protein levels to about 50%, already after 6 h in the tail-suspended rat (P < 0.001), and to about 35% after 8 day bed rest in humans (P < 0.05). In the unloaded rat, melusin loss occurred despite of the maintenance of β1D integrin levels and was not abolished by treatments inhibiting mitochondrial oxidative stress, or nNOS activity and redistribution. Expression of exogenous melusin by cDNA transfection attenuated atrophy of 7 day unloaded rat myofibers (-31%), compared with controls (-48%, P = 0.001), without hampering the decrease in sarcolemmal nNOS activity and the increase in myonuclear FoxO3 and carbonylated myofibers. Infection with melusin-expressing adeno-associated virus ameliorated contractile properties of 7 day unloaded muscles (P ≤ 0.05) and relieved myofiber atrophy (-33%) by reducing Atrogin-1 and MurF-1 transcripts (P ≤ 0.002), despite of a two-fold increase in FoxO3 protein levels (P = 0.03). Atrophy attenuation by exogenous melusin did not result from rescue of Akt, ERK, or focal adhesion kinase activity, because it persisted after co-transfection with dominant-negative kinase forms (P < 0.01). Conversely, melusin cDNA transfection, combined with 7-nitroindazole treatment or with cDNA transfection of the nNOS-interacting chaperone Grp94, abolished 7 day unloaded myofiber atrophy. Disuse/unloading-induced loss of melusin is an early event in muscle atrophy which occurs independently from mitochondrial oxidative stress, nNOS redistribution, and FoxO3 activation. Only preservation of melusin levels and sarcolemmal nNOS localization fully prevented muscle mass loss, demonstrating that both of them act as independent, but complementary, master switches of muscle disuse atrophy.

Sections du résumé

BACKGROUND
Unloading/disuse induces skeletal muscle atrophy in bedridden patients and aged people, who cannot prevent it by means of exercise. Because interventions against known atrophy initiators, such as oxidative stress and neuronal NO synthase (nNOS) redistribution, are only partially effective, we investigated the involvement of melusin, a muscle-specific integrin-associated protein and a recognized regulator of protein kinases and mechanotransduction in cardiomyocytes.
METHODS
Muscle atrophy was induced in the rat soleus by tail suspension and in the human vastus lateralis by bed rest. Melusin expression was investigated at the protein and transcript level and after treatment of tail-suspended rats with atrophy initiator inhibitors. Myofiber size, sarcolemmal nNOS activity, FoxO3 myonuclear localization, and myofiber carbonylation of the unloaded rat soleus were studied after in vivo melusin replacement by cDNA electroporation, and muscle force, myofiber size, and atrogene expression after adeno-associated virus infection. In vivo interference of exogenous melusin with dominant-negative kinases and other atrophy attenuators (Grp94 cDNA; 7-nitroindazole) on size of unloaded rat myofibers was also explored.
RESULTS
Unloading/disuse reduced muscle melusin protein levels to about 50%, already after 6 h in the tail-suspended rat (P < 0.001), and to about 35% after 8 day bed rest in humans (P < 0.05). In the unloaded rat, melusin loss occurred despite of the maintenance of β1D integrin levels and was not abolished by treatments inhibiting mitochondrial oxidative stress, or nNOS activity and redistribution. Expression of exogenous melusin by cDNA transfection attenuated atrophy of 7 day unloaded rat myofibers (-31%), compared with controls (-48%, P = 0.001), without hampering the decrease in sarcolemmal nNOS activity and the increase in myonuclear FoxO3 and carbonylated myofibers. Infection with melusin-expressing adeno-associated virus ameliorated contractile properties of 7 day unloaded muscles (P ≤ 0.05) and relieved myofiber atrophy (-33%) by reducing Atrogin-1 and MurF-1 transcripts (P ≤ 0.002), despite of a two-fold increase in FoxO3 protein levels (P = 0.03). Atrophy attenuation by exogenous melusin did not result from rescue of Akt, ERK, or focal adhesion kinase activity, because it persisted after co-transfection with dominant-negative kinase forms (P < 0.01). Conversely, melusin cDNA transfection, combined with 7-nitroindazole treatment or with cDNA transfection of the nNOS-interacting chaperone Grp94, abolished 7 day unloaded myofiber atrophy.
CONCLUSIONS
Disuse/unloading-induced loss of melusin is an early event in muscle atrophy which occurs independently from mitochondrial oxidative stress, nNOS redistribution, and FoxO3 activation. Only preservation of melusin levels and sarcolemmal nNOS localization fully prevented muscle mass loss, demonstrating that both of them act as independent, but complementary, master switches of muscle disuse atrophy.

Identifiants

pubmed: 32154658
doi: 10.1002/jcsm.12546
pmc: PMC7296270
doi:

Substances chimiques

Cytoskeletal Proteins 0
Forkhead Box Protein O3 0
Itgb1bp2 0
Muscle Proteins 0
NOS1 protein, human EC 1.14.13.39
Nitric Oxide Synthase Type I EC 1.14.13.39

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

802-819

Informations de copyright

© 2020 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Biochim Biophys Acta. 2010 Feb;1803(2):333-41
pubmed: 19914304
Nature. 2012 Apr 04;484(7394):394-8
pubmed: 22495301
J Appl Physiol (1985). 2009 Aug;107(2):549-57
pubmed: 19478193
J Gen Physiol. 2016 Feb;147(2):175-88
pubmed: 26755774
J Physiol. 2014 Jun 15;592(12):2637-52
pubmed: 24710058
FASEB J. 2008 Nov;22(11):3836-45
pubmed: 18644837
FASEB Bioadv. 2019 Apr 11;1(6):364-374
pubmed: 32123839
J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):802-819
pubmed: 32154658
Cell Cycle. 2011 Nov 1;10(21):3678-83
pubmed: 22037254
J Biol Chem. 2003 Apr 18;278(16):13591-4
pubmed: 12556452
Antioxid Redox Signal. 2014 Jun 1;20(16):2479-96
pubmed: 24093939
FASEB J. 2004 Feb;18(2):355-7
pubmed: 14688209
Mol Cell Biol. 2009 Sep;29(17):4798-811
pubmed: 19546233
J Biol Chem. 2016 Apr 8;291(15):8140-9
pubmed: 26865633
Expert Rev Mol Med. 2017 Mar 16;19:e2
pubmed: 28300015
Basic Res Cardiol. 2015 Mar;110(2):10
pubmed: 25653116
Neuromuscul Disord. 2004 Oct;14(10):675-82
pubmed: 15351425
J Pathol. 2018 Dec;246(4):433-446
pubmed: 30066461
Sci Rep. 2019 Jul 16;9(1):10263
pubmed: 31311969
J Biol Chem. 1999 Oct 8;274(41):29282-8
pubmed: 10506186
Am J Physiol Cell Physiol. 2017 May 1;312(5):C627-C637
pubmed: 28274922
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
Pflugers Arch. 2012 Apr;463(5):733-41
pubmed: 22391802
Nat Biotechnol. 2010 Jul;28(7):743-7
pubmed: 20581846
PLoS One. 2014 Apr 29;9(4):e96395
pubmed: 24780915
J Clin Invest. 2007 Sep;117(9):2468-76
pubmed: 17786240
Cell Mol Life Sci. 2019 Aug;76(15):2987-3004
pubmed: 30701284
J Anat. 2013 Nov;223(5):525-36
pubmed: 24010829
Exerc Sport Sci Rev. 2003 Apr;31(2):73-8
pubmed: 12715970
Biomed Res Int. 2014;2014:519310
pubmed: 25313365
J Biol Chem. 2000 Mar 17;275(11):8027-31
pubmed: 10713122
J Appl Physiol (1985). 2019 Apr 1;126(4):894-902
pubmed: 30605403
Nutr Res. 2019 May;65:17-28
pubmed: 30954343
Compr Physiol. 2017 Jun 18;7(3):891-944
pubmed: 28640448
FASEB J. 2003 May;17(8):923-5
pubmed: 12670879
Cardiovasc Res. 2014 Jan 1;101(1):97-107
pubmed: 24130190
Front Physiol. 2018 Mar 20;9:235
pubmed: 29615929
J Appl Physiol (1985). 2001 Mar;90(3):1174-83; discussion 1165
pubmed: 11181634
Front Mol Biosci. 2016 Sep 12;3:53
pubmed: 27672636
J Frailty Aging. 2016;5(1):33-41
pubmed: 26980367
J Biol Chem. 2011 Sep 2;286(35):30837-46
pubmed: 21757757
Am J Physiol Endocrinol Metab. 2014 Sep 15;307(6):E469-84
pubmed: 25096180
FEBS Lett. 2008 Jun 11;582(13):1788-94
pubmed: 18474241
Exp Physiol. 2018 Apr 1;103(4):545-558
pubmed: 29315934
Int J Biochem Cell Biol. 2005 Oct;37(10):1974-84
pubmed: 16087388
Am J Physiol Regul Integr Comp Physiol. 2014 Apr 1;306(7):R470-82
pubmed: 24477538
Am J Physiol Regul Integr Comp Physiol. 2011 Feb;300(2):R408-17
pubmed: 21106911
Elife. 2014 Dec 31;3:
pubmed: 25551293
Am J Physiol Regul Integr Comp Physiol. 2005 Nov;289(5):R1328-37
pubmed: 16002556
Biogerontology. 2009 Oct;10(5):605-11
pubmed: 19083119
Cell. 1999 Nov 12;99(4):355-66
pubmed: 10571178
Am J Physiol Cell Physiol. 2007 Aug;293(2):C712-22
pubmed: 17494629
Cell Adhes Commun. 1998 Mar;5(3):193-205
pubmed: 9686317
Nat Med. 2003 Jan;9(1):68-75
pubmed: 12496958
Basic Res Cardiol. 2014 Jul;109(4):418
pubmed: 24859929
J Biol Chem. 2001 Sep 21;276(38):35636-43
pubmed: 11470779
J Cell Sci. 2011 Oct 15;124(Pt 20):3515-24
pubmed: 22010199
Curr Biol. 2005 Jul 26;15(14):1319-24
pubmed: 16051177
Biochim Biophys Acta. 2011 Nov;1813(11):1961-4
pubmed: 21238503
Free Radic Biol Med. 2016 Sep;98:208-217
pubmed: 26912035

Auteurs

Maurizio Vitadello (M)

Department of Biomedical Sciences, University of Padova, Padova, Italy.
CNR-Institute for Neuroscience, Padova Section, Padova, Italy.

Matteo Sorge (M)

Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.

Elena Percivalle (E)

Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.

Elena Germinario (E)

Department of Biomedical Sciences, University of Padova, Padova, Italy.

Daniela Danieli-Betto (D)

Department of Biomedical Sciences, University of Padova, Padova, Italy.

Emilia Turco (E)

Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.

Guido Tarone (G)

Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.

Mara Brancaccio (M)

Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.

Luisa Gorza (L)

Department of Biomedical Sciences, University of Padova, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH